The chemical class of TCP-c Inhibitors encompasses a diverse range of compounds that indirectly target the TCP-c protein through various signaling pathways and cellular processes. This class primarily consists of kinase inhibitors, reflecting the critical role of kinase-mediated signaling in regulating TCP-c's function. Sorafenib and Sunitinib, for instance, are multi-kinase inhibitors that could modify several pathways potentially connected to TCP-c, highlighting the intertwined nature of signaling networks within cells.
Imatinib and Dasatinib, targeting specific tyrosine kinases, underscore the significance of these enzymes in the regulation of proteins like TCP-c. Their role in this class suggests that TCP-c activity could be modulated through precise intervention in tyrosine kinase signaling.
The inclusion of mTOR inhibitors like Everolimus points to the importance of cell growth and survival pathways in the regulation of TCP-c. This indicates that TCP-c might play a role in cellular processes governed by mTOR signaling. Similarly, EGFR inhibitors such as Gefitinib and Erlotinib hint at a possible connection between epidermal growth factor signaling and TCP-c function.
Crizotinib's role in this class, targeting ALK and MET receptors, further illustrates the complexity of the signaling networks associated with TCP-c. The presence of Pazopanib, a multi-kinase inhibitor affecting VEGF pathways, implies that angiogenesis and vascular growth signaling could intersect with TCP-c's regulatory mechanisms.
Lapatinib and Vandetanib, targeting multiple receptor tyrosine kinases, emphasize the broad spectrum of signaling pathways that could be leveraged to modulate TCP-c activity. The diversity of this chemical class reflects the multifaceted nature of cellular signaling and underscores the potential of these inhibitors to provide insights into TCP-c's biological role.
In summary, the TCP-c Inhibitors class represents a strategic and diverse array of chemicals aimed at elucidating the function of TCP-c by targeting various signaling pathways. This class is instrumental for researchers exploring the intricate web of cellular processes in which TCP-c is involved, offering a window into the protein's regulation and potential biological significance.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A kinase inhibitor, may influence pathways intersecting with TCP-c's function, altering its activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targets tyrosine kinases, potentially modulating signaling pathways that intersect with TCP-c. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
A receptor tyrosine kinase inhibitor, could affect signaling cascades relevant to TCP-c regulation. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
An mTOR inhibitor, could modulate cell growth pathways linked with TCP-c activity. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
A multi-kinase inhibitor, might alter vascular endothelial growth factor pathways intersecting with TCP-c. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR inhibitor, could influence epidermal growth factor signaling linked to TCP-c. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Another EGFR inhibitor, possibly affects similar pathways as Gefitinib, impacting TCP-c. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A Src-family kinase inhibitor, might modulate signaling pathways influencing TCP-c activity. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Inhibits BCR-ABL tyrosine kinase, potentially affecting signaling cascades relevant to TCP-c. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Targets EGFR and HER2, could indirectly modulate TCP-c through these pathways. | ||||||